---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-088029"
form_type: "8-K"
ticker: "APGE"
cik: "0001974640"
company_name: "Apogee Therapeutics, Inc."
filed_at: "2024-08-12T23:59:59+00:00"
generated_at: "2026-05-31T10:10:57.659877+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Apogee reports Q2 net loss $33.8M; cash $789.6M; APG777 Phase 2 dosing started

## Summary
- Q2 2024 net loss $33.8M ($18.9M in Q2 2023); R&D expenses $33.2M, up from $13.9M.
- Cash $789.6M as of June 30, 2024; runway into Q1 2028.
- First patient dosed in APG777 Phase 2 trial; 16-week proof-of-concept data expected 2H2025.
- APG808 interim Phase 1 data Q4 2024; APG990 Phase 1 trial accelerated to Q3 2024.
- Added APG333 (anti-TSLP) to pipeline; entering clinic in 2025; combinations planned.

## SEC filing metadata
- accession: 0001104659-24-088029
- form_type: 8-K
- ticker: APGE
- cik: 0001974640
- company_name: Apogee Therapeutics, Inc.
- filed_at: 2024-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1974640/000110465924088029/0001104659-24-088029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1974640/000110465924088029/tm2421302d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-088029
- JSON: https://secwatch.observer/filing/0001104659-24-088029.json
- Plain text: https://secwatch.observer/filing/0001104659-24-088029.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.